CDC reported continued growth of Candida auris in U.S. healthcare settings from 2022–2024. Clinical cases increased from 2,882 to 6,197, and screening cases increased from 6,226 to 12,432.
CDC emphasizes continued C. auris screening of high-risk patients, appropriate Transmission-Based Precautions, use of disinfectants effective against C. auris, communication of C. auris status during transfers, antifungal susceptibility testing, and strong coordination between healthcare facilities and public health to limit further transmission.